© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to September
oral BET inhibitor
4.5 mg QD, phase I/II for cancer
from bromodomain-focused HTS, SBDD
Journal of Medicinal Chemistry
Bristol Myers Squibb
The BMS BET inhibitor, BMS-986158, is in a Ph. I/IIa trial in advanced cancers. During the optimization of the molecule from a carbazole hit, the authors employed a bold scaffold-hopping…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.